Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01
暂无分享,去创建一个
A. J. Slater | G. McVean | K. King | M. Nelson | Z. Iqbal | A. Dilthey | L. Briley | L. Li | C. Spraggs | C. Cox | P. Newcombe | Z. Iqbal | L. Parham | J. Shen | J. Shen | Michael Nelson | Li Li | Judong Shen | Karen S. King | Alexander T. Dilthey | Zamin Iqbal | Gil McVean | Charles J. Cox
[1] P. Goss,et al. Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Daniel J Schaid,et al. Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] G. McVean,et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications , 2014, Nature Genetics.
[4] D. Goldstein,et al. Pharmacogenetics at 50: Genomic Personalization Comes of Age , 2014, Science Translational Medicine.
[5] Buhm Han,et al. Imputing Amino Acid Polymorphisms in Human Leukocyte Antigens , 2013, PloS one.
[6] B S Weir,et al. HIBAG—HLA genotype imputation with attribute bagging , 2013, The Pharmacogenomics Journal.
[7] M. Pirmohamed,et al. Human leukocyte antigen (HLA)‐B*57:01‐restricted activation of drug‐specific T cells provides the immunological basis for flucloxacillin‐induced liver injury , 2013, Hepatology.
[8] C. Dollery,et al. Lapatinib‐Induced Liver Injury Characterized by Class II HLA and Gilbert's Syndrome Genotypes , 2012, Clinical pharmacology and therapy.
[9] J. McCluskey,et al. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. , 2012, Annual review of pharmacology and toxicology.
[10] Robert M. Plenge,et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis , 2011, Nature Genetics.
[11] M. Daly,et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. , 2011, Gastroenterology.
[12] Martin Goodson,et al. Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. , 2011, Genome research.
[13] Chen-Yang Shen,et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. , 2011, The New England journal of medicine.
[14] K. King,et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Mallal,et al. Pharmacogenetics of drug hypersensitivity. , 2010, Pharmacogenomics.
[16] S. Lewitzky,et al. OC-035 Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a diagnostic test accuracy meta-analysis , 2010, Gut.
[17] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[18] M. Daly,et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin , 2009, Nature Genetics.
[19] James Robinson,et al. The IMGT/HLA database , 2008, Nucleic Acids Res..
[20] David Nolan,et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. , 2008, Immunity.
[21] A Jawaid,et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis , 2008, The Pharmacogenomics Journal.
[22] S. Mallal,et al. HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.
[23] W. Gradishar,et al. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. , 2013, The Lancet. Oncology.
[24] S. Henikoff,et al. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.
[25] Daniel Rios,et al. Bioinformatics Applications Note Databases and Ontologies Deriving the Consequences of Genomic Variants with the Ensembl Api and Snp Effect Predictor , 2022 .